Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Getinge AB, Audiocast with teleconference, Q1'24

By Inderes4/22/2024, 11:00 AM
Getinge

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Mattias Perjos
00:00 - 08:48

Thank you very much. And hi everyone, and welcome to today's conference. With me, I have our CFO, Agneta Palmér, who will present the financials in a moment. We can move directly to page number two to kick things off. So on page number two, we're trying to highlight the key takeaways when it comes to performance for the quarter. Getinge's sales increased by 5.2% in the first quarter. And of this, we had unchanged organic sales despite the challenging comparative figures that we had, because of the release of COVID in China last year, order intake for Getinge as a whole increased by 7.8%, of which organic growth was 2.5%. Due to the positive performance across all three business areas and our main geographical regions. Despite the increased sales, the adjusted EBITA margin was lower than last year, and this is mainly due to continued cost for quality improvements in Acute Care Therapies and the higher costs for input goods and for employees. We continue to have strong Free Cash Flow. And, we have a solid financial position that will enable us to continue to invest in profitable growth going forward. So with that, we can move to page number three, please. So I just wanted to touch on some of the key activities and events during the quarter. So when it comes to the offering to our customers, we received during the quarter our 510(k) for Hemopro 3, which is the new generation of our leading endoscopic vein harvesting technology. In addition to this, we had the launch of our Servo TwinView, and this is a tool that allows medical teams to access and analyze data from the ventilators without having to step inside the sensitive environment in the intensive care unit. We also launched the Aquadis Index, which is a high-capacity water disinfectant, and this is a good combination of better capacity for customers and lower energy consumption. We also strengthened our already attractive portfolio of systems and bioreactors for advanced drug development and production, with, for example, our single-use production reactor. If we then move to sustainability and the continued quality improvement efforts in Cardiac Assist and Cardiopulmonary according to the previously communicated plan or something we spent quite a bit of time on in the corporate for Cardiac Assist. We continue with the field corrections according to the plan that we have in order to regain our CE mark in the middle of April. We also submitted the application for CE certificate approval for the new packaging for the actual therapy consumables. And this is the HLS sets, and these are the ones that generate the highest sales, in this therapeutic area. Also, we soon expect to submit an application for the product to generate the second-highest sales within the cardiopulmonary index of the NSE. Now, from a sustainability perspective, when it comes to the environmental aspect. We have carbon dioxide emissions continuing to develop in a positive direction. We can then move over to page number four please. So as stated earlier, we had order intake growth in the quarter, so reported order intake increased by 7.8% to where a 2.5% was organic and net sales grew by 5.2%, while organic sales growth was flat in the quarters. All regions grew orders organically in the quarter. America is the best performing market currently where we have solid performance in the US. Overall, I would say organic net sales was flat. All in all, despite tough comps in China particularly and APAC more broadly. And also here we have solid performance in the US overall. We can then move over to page number five, please. So when it comes to our guidance for top line, we reiterate that the outlook for 2024 is organic net sales growth in the 2 to 5% range. And in addition to this, we expect our recent acquisitions to contribute 3 to 5 percentage points. So unchanged guidance from that perspective. And we can move over to page number six please. So if you look at the order intake in a bit more detail, Acute Care Therapies had 1.3% organic order intake growth. This was mostly driven by Cardiopulmonary and Cardiac Assist in Life Science. We had 5.6% organic order growth. And this came following a strong quarter in Sterilizers and in our sterile transfer offering. The performance for Life Science remained weak when it comes to Bioprocessing and Surgical Workflows. Finally, we had 3.6% organic growth. And here the growth came from all product categories except for Infection Control, which declined in the quarter. We can then move over to page number seven, please. So one step down and then looking at sales, organic net sales for Acute Care Therapies increased slightly, primarily thanks to large deliveries of hardware in Cardiopulmonary and for both hardware and consumables in Cardiac Assist. And moving on to Life Science, organic net sales for Life Science declined overall by -9.2%. And this was mainly in Sterilizers, Washing Disinfectants, and Isolators. And it was also somewhat challenging when it comes to Bioprocessing sales as data transfer products continue to perform positively within the Life Science business area. In Surgical Workflows, we had 2.4% organic growth and sorry for the increase in net sales. Mainly when it comes to Operating Tables and from a geographic perspective, growth was healthy in the Asian market. Acquisitions were positive in the quarter as well. They contributed to an increase in net sales of 466 million SEK in the first quarter of this year. Currency, when it comes to top line, had a -95 million, or a 1.3% negative impact on net sales for the group. Revenue from service continued to perform positively and combined with large deliveries of consumables in Cardiac Assist. This resulted in growth in recurring revenue as well. We can then move over to page eight, please. So looking at the gross margin, adjusted gross profit increased by 121 million to 3,855 million in the quarter, where FX effects impacted by -29 million for the group as a whole would be adjusted. Gross margin declined by one percentage point as a result of costs related to the previously communicated challenges in Cardiopulmonary. And we also had higher costs for goods and for employees. This was partly offset by price increases and activities to enhance productivity for future therapies. The Adjusted Gross Profit declined by 1.4 percentage points, mainly due to negative mix effects and the costs related to the ongoing improvements in Cardiac Assist and Cardiopulmonary. The margin in Acute Care Therapies was also impacted by negative currency effects. The higher costs for input goods and personnel were partly offset by price increases and positive performance for consumables in Life Science for pulmonary. The Adjusted Gross Profit margin fell by 2.1 percentage points as a result of low absorption, and the higher costs for input goods and employees, while price increases and currency helped to reduce these negative effects. But not entirely. Surgical Workflows. Adjusted Gross Profit increased by 2.2 percentage points, and this was primarily as a result of acquisitions and price increases. So with that summary down to gross margin, we can move over to page number nine. And I'll hand it over to you.

Agneta Palmér
08:49 - 12:11

Thank you Mattias. And hi everyone. A pleasure to be here with you in the first earnings call. So let's have a look at adjusted EBITA. It was down by 13.0. 4%. And the margin came in 2.4 percentage points lower. And adjusted gross profit effect on the margin was negative by 1.2 percentage points due to what was just mentioned by Mattias. So in short, the slightly negative mix costs related to the quality improvement work and increased costs for input goods and personnel were then partly compensated by price increases and productivity. Adjusted for currency, operating expenses (OpEx) had an effect of -2.1 percentage points impact on the margin in the quarter, and that was mainly due to higher costs for employees, both salaries and also in OpEx. We had some effects from the quality improvement work in Cardiopulmonary and in Cardiac Assist. Adjusted for currency, depreciation, and amortization, had a positive effect of 0.3 percentage points on the margin in the quarter. Aesthetics also impacted positively. So all in all, this resulted in an Adjusted EBITA of 842 million Swedish kronor and a margin of 11.2%. Then, please move over to page ten. Free cash flow amounted to almost 1 billion Swedish kronor, and that was positively impacted by changes in Working Capital, mainly attributed to receivables. Last year, you may recall that we had a one-time effect impacting our cash flow. Even adjusting for that, we see an improvement versus last year in Working Capital mostly. Then, thanks to well-managed receivables, working capital days continue to be well below 100. We are now at close to 94 days, which is down a bit more than 35 days from the peak. And we continue to be somewhat below trend on operating Return on Invested Capital (ROIC), with 10.1% on a rolling 12-month basis, which is still above the cost of capital. Let's move to page 11, please. The change in net debt year over year is due to the acquisitions that we finalized in the fourth quarter of 2023. A sequential improvement since then takes us to $7.6 billion in net debt at the end of quarter one. If we adjust for pension liabilities, we are at 5 billion. This brings us to a leverage of 1.4 times EBITDA. And if we adjust for potential liabilities, the leverage is at 0.9 times EBITDA. Cash amounted to approximately 3.4 billion at the end of the quarter. So all in all, we can conclude that the financial position continues to be strong. Let's then move to page 13 and back to you.

Mattias Perjos
12:13 - 13:30

Great. Thank you. So on page 13, I just wanted to quickly summarize the key takeaways from the first quarter of this year. So we continue to grow orders and net sales. And we have launched a large number of value-adding products in the quarter, which I think is a very positive highlight. And we reiterate our guidance for the full year, 2 to 5% organic net sales growth. And in addition, we expect the recent acquisitions to contribute with 3 to 5 percentage points of growth for this year. The adjusted EBITA margin came in 2.4 percentage points below last year, which is explained by the additional cost for quality improvements and also costs for input materials and for personnel. We strengthened our free cash flow versus last year, and we remain with a solid financial position. And if we look at the priorities for 2024, for the remaining of the remainder of the year, it's really about addressing the remaining quality challenges in Acute Care Therapies. It's about working on sustainable productivity improvements and having cost consciousness during the remainder of the year. And of course, last but not least, continue to create value for our customers. And with that said, I open up for questions around this quarter.

Unknown
13:37 - 14:01

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Eric Castle from Danske Bank. Please go ahead.

Unknown
14:02 - 14:15

Hi. Good afternoon everyone. Um, so the first question, how much of the Intra-Aortic Balloon Pump backlog when it comes to hardware, how do you manage it for now? Um, and when do you expect it to start to help the pace of the automatic?

Mattias Perjos
14:19 - 14:28

Uh, I think, Eric, you had quite a bit of background noise there. Can you repeat the second? I only heard the Intra-Aortic Balloon Pump backlog. Can you repeat the second half of the question, please?

Unknown
14:28 - 14:47

Yeah. Sorry. Bit of problems with the headsets. Um, just wondering on the Intra-Aortic Balloon Pump backlog. Um, since, you know, we've delivered a large part of it, how much is left to deliver? And when do you think, you know, making those deliveries will have a positive impact on the orientation of the company?

Mattias Perjos
14:51 - 15:16

Okay, now we don't disclose how much backlog we have when it comes to Intra-Aortic Balloon Pumps. And even though we have delivered some of it and it is gradually reducing, it's a significant backlog still that we will require several months to work through. But we don't provide any forecast on this. Okay. Therefore, it's also difficult to say when it will have an impact on order intake. Of course.

Unknown
15:17 - 15:25

Yeah, I understand. Um, then second question, how large was the scrapping effect in April now compared to Q4?

Mattias Perjos
15:27 - 15:40

Uh, we don't break out scrapping individually. I think we have gradually reducing costs for quality deficiencies, but we don't break down this in details.

Unknown
15:41 - 15:48

Okay, but it was 200 million in Q4. Including scrapping. Is it ballpark the same now, or is it a lot lower?

Agneta Palmér
15:51 - 16:03

So the 200 million was the overall sort of quality related additional costs. And the amount in Q1 was, I would say, roughly half of that.

Unknown
16:05 - 16:23

Okay. Thank you very much. Um, so I'm just wondering now for, uh, so say full year 2024 on the current run rate, cost of quality work in Acute Care Therapies. and then also how much of it you can expect to phase out once the actual packaging issues are resolved.

Agneta Palmér
16:27 - 16:56

So we don't forecast and disclose. But the current trend, we can assume that it is reasonable that it continues through the coming quarters. So roughly half of what we had last year in quality related cost would be a fair assumption. And at this point in time, we would rather come back when we have the numbers solidified. But for now, that is what we are tracking.

Unknown
16:58 - 17:00

All right. Thank you very much. I'll jump back in queue.

Unknown
17:07 - 17:13

The next question comes from Ricard and Kranz from Handelsbanken. Please go ahead.

Unknown
17:15 - 17:36

All right. Good day. And thank you for taking my questions. So first on the ECMO packaging solutions. When should we expect approval and market launches of new packaging solutions? And, how do you feel about the visibility on that timeline? That would be my first one. Thank you.

Mattias Perjos
17:38 - 17:59

Yeah, I think it's, unfortunately, quite a bit out of our hands to predict this. If you look at other instances, it's taken anything from a month to over a year. So, it's very difficult for us to provide any certainty when it comes to this. We're hoping for expedited treatment of this, but it's really not up to us.

Unknown
18:02 - 18:19

All right. Fair enough. And second question on new midterm financial guidance. How come you didn't provide any updated medium term targets in conjunction with Q1? And when should we expect the new targets to be announced? Thank you.

Mattias Perjos
18:20 - 18:48

I think the reason for not providing it in this quarterly report is just that it is a hectic reporting period for everybody, and there's limited time during a quarterly call. So we decided to separate the two events. So I think the planning now is that we will come back on the 15th of May with not updated targets or guidance, but more clarity when it comes to growth of our end markets. And the earnings capacity of the business.

Unknown
18:50 - 18:52

All right, 15 minutes. Perfect. It's very clear. Thank you.

Unknown
18:54 - 18:54

Thank you.

Unknown
18:58 - 19:04

The next question comes from Christopher Lederberg from Carnegie. Please go ahead.

Unknown
19:05 - 19:25

Yeah. Thank you. Some questions for me first. Just coming back to your comment here about quality cost. And when you talked about roughly half of the cost versus losses. Is that also applicable for the full year or was that more common for on a quarterly basis here?

Agneta Palmér
19:27 - 19:31

That is a reasonable assumption for the full year as well.

Unknown
19:32 - 19:52

Okay, good. Then I was a little bit surprised here about the lower shipment of cardiac devices given that the CE mark was suspended again, even though it was pretty late in the quarter, but this CE mark suspension, will that impact deliveries, you think, in the second quarter?

Mattias Perjos
19:54 - 20:05

I think it mainly impacts deliveries in terms of participating in new tenders selling to new clients. It doesn't significantly impact the backlog.

Unknown
20:07 - 20:21

Okay, great. And then finally, for me, if you could maybe comment a little bit about the overall market demand and your confidence in the full-year sales growth guidance range. Thank you.

Mattias Perjos
20:23 - 21:01

Yeah, we feel pretty confident that the range we provide, the 2 to 4 or 5%, is still valid. I think the events that have unfolded in the first quarter have mostly been confirmatory. So that's why we decided to reiterate that and also stay with a 2 to 5% range on this. But I think generally it's a positive. I've called out in the call earlier, but the development in the US, particularly, which is our biggest, most important market, is developing favorably. And on the other end of the range, you have China, which, especially from a life science perspective, remains challenging.

Unknown
21:03 - 21:06

Thank you. Thank you.

Unknown
21:12 - 21:19

The next question comes from Oliver Weinberg from Kepler. Curious? Please go ahead.

Unknown
21:21 - 21:39

Thanks so much for taking my question, and the first one, but can you just provide an update on the launch of the acute ventilator in the US and also the covered stand? Apparently, you and I were trying to enter a new distribution agreement with Cook Medical. Do you still go direct in this kind of space? Any kind of update where you stand on both product lines space?

Mattias Perjos
21:41 - 22:19

Yeah, I think on the first part of the question, it's a bit too early to say. We launched the new event right in the US in Q4 last year. We don't provide any kind of data when it comes to the traction on this. But needless to say, with some of the changes when it comes to our competition, we remain optimistic about the opportunities for the medium to longer term. When it comes to the distribution agreement with Cook Medical, it is an exclusive distribution agreement in the US. So it means that we do not sell directly ourselves. It's taken over by Cook Medical in the US.

Unknown
22:21 - 22:27

And any kind of color, how quickly you can move back to the market in terms of earlier sales that you had in the past.

Mattias Perjos
22:28 - 22:47

No, too early to say. I think we've entered into this agreement because we are both enthusiastic about the opportunities here. They have a sales force that is many multiples bigger than our own. So that should realistically have an impact. But it's very difficult to forecast the pace of this pickup.

Unknown
22:48 - 23:00

Okay. Understood. And secondly, just on this CE mark issue around cardiac assist, which obviously was pulled again a couple of months ago. So can you just share your take, what happened then and what are exactly the steps that you now have to go through?

Mattias Perjos
23:03 - 24:04

Uh, yeah. To share. Exactly. It's a bit long-winded, but I think the main summary is that we haven't been fast enough when it comes to implementing some of the field safety actions that are needed in certain geographies. Uh, so the notified body was not happy with the progress made. So that's the main reason for the new suspension of the CMR part of that. Those delays were triggered by a lack of components that we had during the first half of last year. So those are now mitigated. And we're in a much better situation to do the field safety actions with better speed. And um, so we're cautiously optimistic that we'll be able to do that part of the remediation work, but again, difficult to provide any detailed guidance on this going forward. I think we are in agreement and we are clear about the work that needs to be done. But it's a little bit difficult to forecast the pace.

Unknown
24:05 - 24:22

Understood. And last question from my side, just in terms of kind of full-year margin outlook in the past, you provided some kind of color as part of the quotes. So, I mean, the Street is currently looking for a 13.6% EBITDA margin for the full year. Is that a level you feel comfortable with, or do you see more to the downside of it?

Mattias Perjos
24:24 - 24:50

Yeah, we know very well I don't know more than a year. We said that we will have an improvement in 2024 compared to 2023. But we've not been more granular about this. And I think the next information milestone is going to be on the 15th of May, where we provide a bit more explanation about both the end market growth but also our potential to improve profitability.

Unknown
24:51 - 24:52

Understood. Thanks so much.

Unknown
24:53 - 24:54

Thank you.

Unknown
24:59 - 25:05

The next question comes from Mathias Waddesdon from Seb. Please go ahead.

Unknown
25:09 - 25:10

Hi. Thank you.

Unknown
25:10 - 25:22

I think you said the transfer products develop positively. Could you elaborate a little bit on this and perhaps update us as well on the momentum around this device? That's the first one.

Mattias Perjos
25:25 - 25:49

Yeah. When we talk about style transfer. The main category there is data bags. And it's difficult to provide any more color. We don't break this down into any kind of subsegment reporting. So, no additional numbers there. It's just that it seems to be bottoming out. This destocking that's been going on for a while, a slightly better momentum with at least some selected customers in that subcategory.

Unknown
25:50 - 26:10

Getinge's Q1 2024 financial report highlights a strong quarter for Surgical Workflows, maintaining extraordinary levels. Do you expect more normal workflow sales. From here, in the upcoming quarters, or how should we see it from here?

Mattias Perjos
26:11 - 26:34

It depends on what you mean. With more and more normal. I think we have said we have a good momentum from the acquisitions. We have good traction when it comes to operating tables, both the legacy portfolio and also our newly launched current table. And that's been well-received. So we don't provide the EBITA guidance they are bundling with the 2 to 5% growth for the full year.

Unknown
26:36 - 26:37

Okay. Good.

Unknown
26:37 - 26:55

Maybe I touched a little bit on it, but the two acquisitions seem to perform quite well. Could you perhaps touch upon the development for those two companies that you acquired last year until now, and maybe also touch a little bit on the margin performance if that's possible? That's my last one.

Unknown
26:57 - 26:58

Yeah.

Mattias Perjos
26:58 - 28:06

I think if we thought with help. Mark, they've had a very good start as part of Getinge, both initially in the fourth quarter when they joined last year. And this momentum has continued through Q1 2024 as well. We're very happy with this addition to our portfolio. It's really well received by customers. And, growth-wise, they are a little bit ahead of our expectations of what we had in the business case when we acquired them. And also from the margin standpoint, they're doing a little bit better. So, uh, so positive on all fronts, I would say there and a bit similar to when it comes to high purity in New England. I mean, this is a younger company, so not profitable when we acquired them, but they have plenty of capacity to expand in a very attractive niche. And I think the interaction with customers during the first few months has confirmed our positive view on the portfolio and the potential of the portfolio. And, uh, the growth potential. And, with the leverage effect from growth, we believe that they will turn into a more profitable part of Life Science as well.

Unknown
28:08 - 28:09

Thank you very much.

Unknown
28:11 - 28:12

Thank you.

Unknown
28:17 - 28:23

The next question comes from David Adlington from J.P. Morgan. Morgan, please go ahead.

Unknown
28:25 - 28:26

Hey guys!

Unknown
28:26 - 28:53

Thanks for checking the questions. Most of them have been asked already. Maybe just on the event on the 15th of May, is that a capital markets event, or is it just going to be a call and a quick update in terms of the longer-term expectations? Secondly, just wondered why we've seen an uptick in R&D capitalization this quarter. And then finally, just in terms of the recovery in China, I just wondered what visibility there is. Please.

Unknown
28:56 - 28:56

Yeah, sure.

Mattias Perjos
28:56 - 29:46

I'll tell you. Start with the first one here. So we haven't labeled the event as such. But it is more of an informal update and closing the loop on some of the question marks that have been there around the end market growth, divided into some of the sub-segments that are most important to us. And also trying to help the understanding of the cost evolution over the last few years, the progress when it comes to quality improvement work, and the impact it has had on the business. And likely we'll have, uh, going forward and also a bit on the mix of the business and what we expect from that. So, it is more of an informal update, I would say. And, uh, anything else. And the second question, I didn't hear, so maybe I never heard it.

Agneta Palmér
29:46 - 29:50

It was regarding the R&D capitalization in the quarter, is that correct?

Unknown
29:51 - 29:51

Correct.

Agneta Palmér
29:53 - 30:10

Yeah. So, to pursue this. A bit of timing depending on where we are in different large projects. But secondly, it is that we are investing resources in the future portfolio and in some of these quality improvement areas specifically.

Unknown
30:15 - 30:16

Thank you.

Agneta Palmér
30:18 - 30:20

And the third question was.

Unknown
30:22 - 30:28

The next question comes from Robert Davies from Morgan Stanley. Please go ahead.

Unknown
30:32 - 31:37

Morning. Thanks for taking my questions. I had a few, one was just on the corporate cost line. I noticed that came in, quite a bit below where consensus expectations are. I just wondered if you could provide any color on what drove that and what the expectation for that line item is for the full year. That was my first question. My second one was following up on something you mentioned earlier about China. We have seen some of your peers highlight a potential stimulus package in China that could push increased investments in medtech and life sciences more broadly. I'd just be curious to get your thoughts around the potential magnitude of timing and size of that sort of stimulus package, what you're hearing on the ground. And then just on the capital markets event that you were highlighting, potentially looking at the margin targets, is that something you would lean towards having a band or specific number? Could you just provide any color on what the thought process is there around the margin expectations for the group? Thank you.

Agneta Palmér
31:40 - 31:47

So if I start by the corporate costs line, it is not a trend shift, it is more of a timing of some cost items.

Unknown
31:52 - 31:52

Yeah.

Mattias Perjos
31:52 - 32:55

So. Yeah. So don't extrapolate that number. It's better to go with the old ones. And when it comes to China and bioprocessing, I think we remain a bit more pessimistic. We hear mixed views from our peers, partly related to stimulus, but also partly related to just general market development. We see that it doesn't seem to be getting any worse. It's bottoming out, but it's very difficult to predict any uptake or stimulus or not. So we remain humble that we don't really have great visibility when it comes to China, I think. And when it comes to the Capital Markets Day, I think it's probably better to just wait for it's not the Capital Markets Day, but it's the capital markets update. Better to just wait for that. I don't want to give any preview here on what exactly to expect. We're trying to gather feedback from the market. What's desired and trying to match that with what is actually possible to realistically provide for us.

Unknown
32:57 - 33:25

Maybe if I can just squeeze one final one just around Acute Care Therapies margins. I just want once you're sorted through these packaging remediation issues, is there any reason that margins should not go back into those low 20s? Are you still, I know on previous calls I think you'd mentioned a sort of a hope or an expectation of maybe getting to mid-20s in that business. So just be kind of curious what was the last or latest public commentary on the trajectory and timeline of Acute Care Therapies specifically? Is it just a packaging issue or is there anything else?

Mattias Perjos
33:27 - 33:58

It's not just a packaging issue, it is. It is packaging. It's remediation work in Cardiac Assist. It's upgrading of all the platforms. There is both quality system work and a number of quality product engineering, product maintenance updates that need to be done. So it is a heightened cost level overall. Having said all that though, just to answer the question, you know, there is no reason why the margin shouldn't go back above 20%.

Unknown
34:00 - 34:03

Understood. Thank you very much. Thank you.

Unknown
34:08 - 34:15

The next question comes from Patrick Lin from DNB Markets. Please go ahead.

Unknown
34:15 - 34:31

And thanks for taking the questions. Uh, just want to come back once again to the event on the 15th of May. So the long-term financial targets that you have for 2022 to 2025, we should not expect you to change those at this event.

Mattias Perjos
34:34 - 34:42

And we will have to come back on the event as such. This is a process that we're still going through, so I don't want to exclude anything at this point.

Unknown
34:44 - 35:04

Okay. Great. Good. Uh, then I also had a question on, um, when I look at the group items for this quarter, it's significantly lower than what we saw during the last four quarters, during 2023 or the specific reasons. And is this the level that we should expect going forward?

Agneta Palmér
35:06 - 35:10

And so you're looking at the corporate cost line. Correct.

Unknown
35:11 - 35:14

And that's the group items in EBITDA. Yeah.

Unknown
35:14 - 35:15

Yeah.

Agneta Palmér
35:15 - 35:26

And it is not a trend shift. So we should not extrapolate this current level. It is about the timing of some costs. So it is rather to look at the historical levels.

Unknown
35:27 - 35:52

Okay great. So going forward we should more look at what we saw last year rather than this quarter. And then my last question is, I mean, you mentioned in the report that you signed a distribution agreement with Cook for the Covid stents. Um, and any particular reason why you do that and why don't you go it alone, so to speak, in the US?

Mattias Perjos
35:53 - 36:44

Yeah. I think it's a great question. I think what's happened since, uh, 2017 and how this market has evolved. I think if you keep in mind that we were basically alone in the Covid space. So this part of the space, uh, in 2017 and we had a couple of new competitors. And so, the market landscape has changed quite a bit. And, looking at the resources that we have when it comes to the commercial part of driving this business, we just came to the conclusion that to make that investment organically ourselves right now just wouldn't be a good capital allocation compared to other options that we have. So therefore, in addition to this, Cook Medical was looking for a product as an addition to their portfolio. So it was a really good match to join forces with them. So that's the rationale behind this.

Unknown
36:46 - 36:49

Hey. Great. Thank you very much, guys.

Unknown
36:50 - 36:50

Thank you.

Unknown
36:56 - 37:02

The next question comes from David Johansson from Nordic markets. Please go ahead.

Unknown
37:05 - 37:08

Thanks for taking my questions. I have two. So first.

Unknown
37:08 - 37:09

I'll follow up.

Unknown
37:09 - 37:43

On the results in surgical workflows. How much of the margin improvement was driven by HealthMark, and how much was sort of underlying improvements in the quarter? And secondly, on the critical care business. There looks to be some meaningful changes looking at the competitive landscape in the US, especially with one competitor exiting. So it would be interesting to hear your thoughts on this market specifically. Now after these changes and how you feel about the potential now looking at replacement volumes over the next few years. Thanks.

Unknown
37:45 - 37:45

Yeah.

Agneta Palmér
37:45 - 37:56

So if we start with the surgical workflows, it was both an underlying improvement in the legacy business, so to speak, and the positive contribution margin-wise from HealthMark.

Mattias Perjos
38:01 - 38:25

Okay. And if we move to the critical care space, I agree with your conclusion. I think it is interesting now to see what happens in the wake of some of these players that are exiting the market, but it is still early days and difficult to predict the impact of this. We're cautiously optimistic, and this should definitely benefit us, but it's very difficult to judge the timing and the impact of this.

Unknown
38:27 - 38:27

Thanks.

Unknown
38:29 - 38:30

Okay. Thank you.

Unknown
38:35 - 38:41

The next question comes from Robert Davies from Morgan Stanley. Please go ahead.

Unknown
38:44 - 39:17

So thank you. I just had a couple of follow-ups. One was, if you could quantify the size of the revenue contribution from High Purity and HealthMark in the quarter, that was one question I had. Um, and then just in terms of your, um, full year guidance around, um, organic sales growth, how do you see the risk to that, given that you've posted zero in the first quarter? Um, and the comps obviously are easier in Q2, but they get, um, much, much stronger by the time you reach Q4. I just wondered if you could kind of contextualize the seasonality or how you're thinking about that. Thank you.

Mattias Perjos
39:27 - 39:30

Can you repeat the second half of the question first, please?

Unknown
39:31 - 39:57

Yeah. Sorry. The first one was on the revenue contribution from High Purity and Health Mart. And then the second part of the question was just how you feel about the full year guidance on organic sales growth of, um, 2 to 5%, given you've obviously started the first quarter at zero and Q3 and Q4 are seeing much stronger comps. So I think up to 10% by the fourth quarter. So just wanted to get a sense of what was going to drive that sort of improved growth in the second half. Thank you.

Mattias Perjos
40:00 - 40:06

Yeah. On the first bit, I think we had that actually in the material. So we'll come back on the, uh, or.

Agneta Palmér
40:07 - 40:10

It contributes with an increase in the quarter of 466 million.

Unknown
40:10 - 40:11

You can see that.

Mattias Perjos
40:11 - 40:16

In one of the tables on the presentation and the commercial sources. Okay.

Unknown
40:16 - 40:16

Thank you.

Mattias Perjos
40:17 - 41:18

Yeah. And, uh, when it comes to organic growth, I think we remain optimistic that we can be inside the window of 2 to 5% based on the book that we had now with pickup in order intake, which is positive, of course, looking as well when it comes to the upcoming quarters, uh, Q1 was, uh, a bit more difficult than some of the ones that we have ahead of us now, given the Covid restrictions that were lifted in China at the end of 2022, which led to an increase in volume in primarily clinical care, but also to some extent, you, uh, in the first quarter of last year. So that's some of the reasons. And uh, in addition to this, we hope to become increasingly less constrained when it comes to supply, uh, challenges, both quality related and supply chain challenges as well. Uh, just want to highlight that we're not out of the woods there. So there's some uncertainty linked to this, but with the visibility that we have, we remain confident that 2 to 5% organic is realistic.

Unknown
41:20 - 41:21

That's great. Thank you.

Unknown
41:23 - 41:23

Thank you.

Unknown
41:31 - 41:38

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Unknown
41:39 - 41:39

Great.

Mattias Perjos
41:39 - 42:28

Thank you everyone for a lot of the good questions here. And thanks for tuning in. So just to summarize again, we've closed out the first quarter and I think the main positives being organic order intake growth, a good momentum from the companies that we acquired during last year as well, and a string of nice product launches that will be adding value to customers and patients for many years to come. Uh, on the negative side, we're continuing to work through a lot of the quality challenges that we've had here. So we're making good progress, but they will remain with us for the remainder of 2024. And finally, we will come back on the 15th of May with a slightly more granular update when it comes to growth and profitability of our business. So once again, thanks for joining the call today.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…